Geron Corporation to Present at Biotechnology Industry Organization Investor Forum
MENLO PARK, Calif., Oct. 9, 2007 – Geron Corporation (Nasdaq: GERN) today announced that Alan B. Colowick, Ph.D., M.P.H., president, oncology, will present an update of the company’s oncology programs at 10:45 a.m. PDT on Wednesday, Oct. 10, 2007, at the Biotechnology Industry Organization Investor Forum in San Francisco.
The update will cover information about Geron’s portfolio of anti–cancer therapies, including its telomerase inhibitor drug (GRN163L) and its telomerase therapeutic vaccine (GRNVAC1).
Geron is developing first–in–class biopharmaceuticals for the treatment of cancer and degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS. The company is advancing an anti–cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem cell–based therapeutics, with its spinal cord injury treatment anticipated to be the first product to enter clinical development. For more information, visit www.geron.com.
CONTACTS:
Media and Investors: David Schull, Russo Partners, LLC, 858–717–2310, david.schull@russopartnersllc.com
